More articles from Current Drug Therapy

  • Reducing the risks when using benzodiazepines to treat insomnia: A public health approach
    Vania Modesto-Lowe, MD, MPH, Margaret M. Chaplin, MD, Roberto León-Barriera, MD and Lakshit Jain, MD
    Cleveland Clinic Journal of Medicine May 2024, 91 (5) 293-299; DOI: https://doi.org/10.3949/ccjm.91a.23061

    The authors review measures for preventing harm before benzodiazepines are prescribed, decreasing harm within 4 weeks after they are prescribed, and limiting harmful effects of long-term prescribing.

  • Nonstatin therapy to reduce low-density lipoprotein cholesterol and improve cardiovascular outcomes
    Abhayjit Singh, MD and Leslie S. Cho, MD
    Cleveland Clinic Journal of Medicine January 2024, 91 (1) 53-63; DOI: https://doi.org/10.3949/ccjm.91a.23058

    Several new nonstatin medications have been approved in recent years, with robust data from clinical trials supporting their use in atherosclerotic disease.

  • A practical guide for buprenorphine initiation in the primary care setting
    Roberto León-Barriera, MD, Samantha Jayne Zwiebel, MD, MA and Vania Modesto-Lowe, MD, MPH
    Cleveland Clinic Journal of Medicine September 2023, 90 (9) 557-564; DOI: https://doi.org/10.3949/ccjm.90a.23022

    The authors review changes in prescribing laws and outline buprenorphine induction protocols that can be adopted in the primary care setting.

  • Update on current contraceptive options: A case-based discussion of efficacy, eligibility, and use
    Update on current contraceptive options: A case-based discussion of efficacy, eligibility, and use
    Alexa Nicole Fiffick, DO, MBS, NCMP, Tara K. Iyer, MD, NCMP, Tiffany Cochran, MD, MA, NCMP and Pelin Batur, MD, FACP, NCMP
    Cleveland Clinic Journal of Medicine March 2023, 90 (3) 181-190; DOI: https://doi.org/10.3949/ccjm.90a.22075

    Rates of unintended pregnancy are high in the United States. Clinicians need to be well-informed about the full spectrum of contraceptive options to improve reproductive autonomy.

  • Antiobesity drug therapy: An individualized and comprehensive approach
    Yael Mauer, MD, MPH, Marcie Parker, PharmD, BCACP and Sangeeta R. Kashyap, MD
    Cleveland Clinic Journal of Medicine August 2021, 88 (8) 440-448; DOI: https://doi.org/10.3949/ccjm.88a.20080

    As part of a comprehensive plan, these drugs can provide lasting obesity control and additional health benefits, including decreased cardiovascular risk.

  • Prescribing testosterone and DHEA: The role of androgens in women
    Taryn Smith, MD, NCMP and Pelin Batur, MD, FACP, NCMP
    Cleveland Clinic Journal of Medicine January 2021, 88 (1) 35-43; DOI: https://doi.org/10.3949/ccjm.88a.20030

    Androgens play an important physiologic role and can promote sexual health.

  • The role of SGLT-2 inhibitors in managing type 2 diabetes
    Yumiko Tsushima, MD, M. Cecilia Lansang, MD, MPH and Vinni Makin, MBBS, MD, FACE
    Cleveland Clinic Journal of Medicine January 2021, 88 (1) 47-58; DOI: https://doi.org/10.3949/ccjm.88a.20088

    These drugs improve glycemic control and offer cardiovascular and metabolic benefits.

  • CGRP antagonists for decreasing migraine frequency: New options, long overdue
    Julia Bucklan, DO and Zubair Ahmed, MD
    Cleveland Clinic Journal of Medicine April 2020, 87 (4) 211-218; DOI: https://doi.org/10.3949/ccjm.87a.19048

    CGRP drugs are an exciting frontier, but migraine management is still a combination of lifestyle changes plus treatment.

  • ACE inhibitors and ARBs: Managing potassium and renal function
    Tasnim Momoniat, MBCHB, MRCP (UK), Duha Ilyas, MBBS, MRCP (UK) and Sunil Bhandari, MBCHB, FRCP, PhD, M CLIN EDU, FHEA
    Cleveland Clinic Journal of Medicine September 2019, 86 (9) 601-607; DOI: https://doi.org/10.3949/ccjm.86a.18024

    Concern about hyperkalemia and a decline in renal function has led to underuse of these drugs.

  • Diabetes management: Beyond hemoglobin A1c
    Vinni Makin, MBBS, MD, FACE and M. Cecilia Lansang, MD, MPH
    Cleveland Clinic Journal of Medicine September 2019, 86 (9) 595-600; DOI: https://doi.org/10.3949/ccjm.86a.18031

    Other factors include cardiovascular benefit, weight control, hypoglycemia risk, and cost.

Pages